India  

Bharat Biotech

Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Bharat Biotech: Indian multinational biotechnology company and vaccine manufacturer
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in the city of Hyderabad, India engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

0
shares
ShareTweetSavePostSend
 
Bharat Biotech’s Covaxin safe for children of  2to18 years says Lancet Journal Oneindia News*News [Video]

Bharat Biotech’s Covaxin safe for children of 2to18 years says Lancet Journal Oneindia News*News

The manufacturers of the Covid-19 vaccine Covaxin, Bharat Biotech have said that their vaccine is safe for use on children between the age group of 2 to 18 years. #Covaxin #BharatBiotech..

Credit: Oneindia     Duration: 01:41Published

You Might Like


Bharat Biotech's intranasal Covid-19 vaccine to get DCGI nod soon? Here's what we know

The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as a booster dose.
DNA - Published

Bharat Biotech expects regulator's nod for intranasal Covid-19 vaccine in August

Bharat Biotech, which is working on an intranasal Covid-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, chairman and managing director of the company,..
IndiaTimes - Published

Biological E's Corbevax, Bharat Biotech's Covaxin get NTAGI's nod for use children aged 5-12 years

Prime Minister Narendra Modi emphasised that all eligible children get the Covid-19 vaccine as soon as possible via "special programmes" in schools.
DNA - Published

Bharat Biotech's Covid nasal vaccine phase 3 trials completed

The company will submit its data to the Drugs Controller General of India (DCGI) next month, said Dr Krishna Ella, Bharat Biotech chief.
DNA - Published Also reported by •IndiaTimes

Covaxin safe for 2-18 age group: BB study

It conducted phase II/III, open-label, and multicentre study to evaluate the safety, reactogenicity and immunogenicity of Covaxin in children and adolescents in the 2-18 years of age group between..
IndiaTimes - Published

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a..
IndiaTimes - Published

FDA lifts hold on Covaxin's clinical trials in US

The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued by..
IndiaTimes - Published

Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold

The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin that were being conducted in..
IndiaTimes - Published

CEPI partners consortium of Bharat Biotech, Sydney University & ExcellGene to develop variant-proof SARS-CoV-2 vaccine


IndiaTimes - Published

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

Bharat Biotech has sought permission from India's drug regulator to conduct a phase 2/3 study of its Covid vaccine Covaxin as a booster dose among those aged two to 18 years, sources told PTI...
IndiaTimes - Published

MEA asked Bharat Biotech to act on WHO suspension? Officials refute claim


IndiaTimes - Published

Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world..
IndiaTimes - Published

DCGI gives approval for Bharat Biotech's Covaxin for children aged 6-12

The Drug Controller General of India (DCGI) has given a restricted emergency use approval for Bharat Biotech's Covid-19 vaccine, Covaxin, for children between the age of six and 12. A Subject Expert..
IndiaTimes - Published Also reported by •DNA

DCGI grants approval to Corbevax for kids aged 5-12, Covaxin for 6-12 age group

The Drug Controller General of India (DCGI) on Tuesday granted emergency use approval to Covid-19 vaccines, Covaxin and Corbevax, for children below 12. Bharat Biotech's Covaxin has got nod for use in..
IndiaTimes - Published

Bharat Biotech asked to provide more data on Covid-19 vaccine Covaxin for children aged below 12

The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its Covid-19 vaccine, Covaxin, for administering it to children aged..
IndiaTimes - Published

Fallout of WHO observations: Covaxin's Phase 2/3 trials in US put on hold

The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA. Bharat Biotech's partner for US and Canada for Covaxin, the FDA's..
IndiaTimes - Published

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot


IndiaTimes - Published

Covishield, Covaxin prices slashed ahead of booster drive expansion

Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..
IndiaTimes - Published

Japan recognises Covaxin to facilitate travel from April 10: Bharat Biotech


IndiaTimes - Published

'Amid drop in demand, Bharat Biotech slowed Covaxin production since February'


IndiaTimes - Published

No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech

With WHO announcing the suspension of Covaxin supply through UN procurement agencies, Bharat Biotech sources said on Monday the pharma company has not supplied the COVID-19 vaccine to any UN agency and..
IndiaTimes - Published

SII's Covovax becomes the fourth jab to be used for vaccination of 12-17 age group

Covovax is the 4th Covid vaccine authorised for administration in 12 years and above after ZyCoV-D, Bharat Biotech's Covaxin, Biological E's Corbevax.
DNA - Published

WHO suspends Covaxin supply for UN procurement citing GMP deficiencies at Bharat Biotech facilities


IndiaTimes - Published

Will Covid-19 nasal vaccine prove effective against infection? AIIMS expert says THIS

AIIMS expert Dr Sanjay Rai talked about the effectiveness of the Bharat Biotech nasal vaccine against the Covid-19 infection.
DNA - Published

Covaxin showed better antibody response in 2-18 year olds than adults: Bharat Biotech


IndiaTimes - Published

'Precautionary dose' for 60+ with comorbidities 9 months after 2nd dose - Check new guidelines

Bharat Biotech's Covaxin has been granted approval for restricted use in an emergency situation in the age group between 12 and 18 years.
DNA - Published

Documents required to register children between 15-18 years on CoWIN App - Complete list here

Meanwhile, Bharat Biotech received the nod from the DGCI for emergency use of vaccines in children above the age of 12 years.
DNA - Published

BREAKING: Bharat Biotech gets DGCI approval for emergency vaccination for kids aged 12-18

Amid rising cases of Omicron in India, DGCI has given Bharat Biotech a green signal for the emergency use of its vaccine for kids aged between 12 to 18 years.
DNA - Published

Bharat Biotech seeks DCGI's nod for its intranasal COVID-19 booster dose clinical trials

The company is hoping for early approval for the trails of the intranasal COVID-19 booster given the fast spread of the Omicron variant.
DNA - Published Also reported by •IndiaTimes

Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: MoS Health

The current vaccine production capacity of Covishield, manufactured by the Serum Institute of India, is approximately 250-275 million doses per month while it is about 50-60 million doses per month for..
IndiaTimes - Published

Lancet Infectious Diseases study compare well with phase 3 clinical trials of Covaxin: Bharat Biotech

Commenting on the study of the Lancet Infectious Diseases on the effectiveness of Covaxin (BBV152) against symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has said that the results compare well..
IndiaTimes - Published

Canada set to recognise Covaxin from Nov 30

In a big relief to travellers from India, Canada will recognise Bharat Biotech's Covaxin from November 30. It has expanded its list of WHO-approved Covid-19 vaccines that will be accepted for travel to..
IndiaTimes - Published

Lost 10 years of life in 18 months due to Covaxin stress, says Krishna Ella

In a face-to-face interview, Ella opened up to TOI about the thrill of developing India’s first indigenous Covid-19 vaccine, but also spoke about the dangers and controversies that dogged the company..
IndiaTimes - Published

Bharat Biotech's Covaxin safe, 77.8% effective against symptomatic COVID-19: Lancet

The findings published by Lancet show Covaxin has 77.8% efficacy against symptomatic COVID-19 and a 63.6% protection against asymptomatic patients.
DNA - Published

When should you take booster shot of COVID-19 vaccine? Bharat Biotech Chairman says THIS

Bharat Biotech is also looking at nasal vaccine as a booster dose, Chairman and Managing Director Krishna Ella said.
DNA - Published

Covid: Booster dose of vaccine required if virus gets mutated, says Bharat Biotech Chairman

People will need booster doses of the Covid-19 vaccine if the virus gets mutated, said chairman and MD of Bharat Biotech, Dr Krishna Ella. "If there is a mutated Covid-19 virus then a booster is..
IndiaTimes - Published

UK to add Bharat Biotech's Covaxin to approved vaccine list from November 22

The UK will be approving Bharat Biotech's Covaxin for its updated vaccine list for international travelers from November 22.
DNA - Published

Covid-19: Govt to start vaccination for kids only after nod to Covaxin

Children may have to wait for some more time to get vaccinated against Covid-19 as the government will start immunisation for kids only after Bharat Biotech's Covaxin is approved for use which might..
IndiaTimes - Published

UK to recognise Covaxin from Nov 22; US welcomes inclusion of Bharat Biotech vaccine in WHO-approved list

The UK has said it will recognise made-in-India Covaxin starting November 22, while the US Centers for Disease Control and Prevention (CDC) on Monday described the World Health Organization’s..
IndiaTimes - Published

Bharat Biotech's US partner Ocugen seeks Covaxin approval for children

Covaxin uses the same Vero Cell manufacturing platform as other childhood vaccines, including the inactivated polio vaccine.
DNA - Published Also reported by •IndiaTimes

Bharat Biotech's US partner Ocugen files EUA request with FDA for paediatric use of Covaxin


IndiaTimes - Published

Travellers vaccinated with Bharat Biotech's Covaxin can now enter US

Covaxin developed by Hyderabad-based Bharat Biotech in partnership with the Indian Council of Medical Research has a 78% efficacy rate against COVID.
DNA - Published

How WHO nod for Bharat Biotech's Covaxin will benefit Indians - Know here

WHO has approved Bharat Biotech's Covaxin for emergency use listing yesterday, and this move can be beneficial for many Indians.
DNA - Published

Bharat Biotech gets DCGI nod for shelf-life extension of its COVID-19 vaccine Covaxin

Bharat Biotech had submitted its data to the drug regulator and sought a shelf-life extension for its vaccine.
DNA - Published

WHO approves Bharat Biotech's Covaxin for emergency use listing

WHO has added Bharat Biotech's vaccine Covaxin to the portfolio of vaccines validated by it for the prevention of COVID-19.
DNA - Published Also reported by •IndiaTimes

Covaxin gets shelf life extension up to 12 months

Vaccine maker Bharat Biotech on Wednesday said the Central Drugs Standard Control Organisation (CDSCO) has approved the extension of shelf life of Covid-19 vaccine Covaxin up to 12 months from the date..
IndiaTimes - Published


 Page 1  〉